藥明康德(603259.SH):設全球首席投資官 由胡正國出任
格隆匯5月21日丨藥明康德(603259.SH)公佈,公司第二屆董事會第一次會議召開,審議通過《關於聘任公司全球首席投資官的議案》,同意設全球首席投資官,並聘任Edward Hu(胡正國)為公司全球首席投資官,領導公司全球範圍內的投資、併購及新業務發展事務,任期自本次董事會審議通過之日起,至第二屆董事會任期屆滿之日止。
胡正國,1962年12月出生,碩士,美國國籍,已取得中華人民共和國外國人永久居留證。1983年-1985年,於杭州大學科學儀器廠任工程師;1988年-1989年,於中國大恆公司任經理;1989年-1990年,於德國Jurid Bremsbrag GmbH任工程師;1996年-1998年,擔任美國默沙東高級財務分析師;1998年-2000年,擔任美國Biogen Inc.商業策劃經理;2000年-2007年,歷任美國Tanox, Inc. 財務總監,運營副總裁,高級副總裁及首席運營官;2007年-2017年,歷任藥明有限常務副總裁及首席運營官,WuXi Cayman(無錫開曼)常務副總裁及首席運營官、首席運營官及首席財務官、藥明有限首席財務官及首席投資官。胡正國同時擔任WuXi Biologics(Cayman)Inc.(股票代碼:2269.HK)非執行董事及其多家下屬子公司的董事;亦擔任New WuXi Life Science Investment Limited的董事及其多家下屬子公司的董事。2017年3月至2019年1月擔任公司首席財務官、首席投資官,2017年3月至今擔任公司執行董事。2018年8月至2020年5月擔任公司聯席首席執行官。現任公司副董事長、全球首席投資官。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.